Recent discussions on X about Invivyd, Inc. (IVVD) have centered around the company's Q2 2025 financial results and significant insider selling. Posts on the platform highlight a mix of reactions to the earnings report, with some noting revenue growth of over 400% year-over-year despite missing analyst expectations. The sharp decline in stock price, down 28% in the past week as reported by web sources, has fueled intense debates among users.
Additionally, the sale of shares by key executives, including the Chief Scientific Officer, has sparked concern among some on X, with questions arising about the timing and implications of these transactions. Despite the volatility, a few users remain optimistic, pointing to the company's ongoing innovation in the biotech space and analyst reiterations of a Buy rating with a much higher price target. These contrasting views keep the conversation dynamic and closely watched by investors.
Note: This discussion summary was generated from an AI condensation of post data.
Invivyd, Inc. Insider Trading Activity
Invivyd, Inc. insiders have traded $IVVD stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $IVVD stock by insiders over the last 6 months:
- JILL ANDERSEN (Chief Legal Officer, Secretary) has made 0 purchases and 2 sales selling 82,754 shares for an estimated $49,676.
- WILLIAM E. DUKE (Chief Financial Officer) has made 0 purchases and 2 sales selling 49,656 shares for an estimated $29,808.
- JULIE GREEN (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 49,656 shares for an estimated $29,808.
- TIMOTHY EDWARD LEE (Chief Commercial Officer) has made 0 purchases and 2 sales selling 49,656 shares for an estimated $29,808.
- ROBERT D. III ALLEN (Chief Scientific Officer) has made 0 purchases and 2 sales selling 45,932 shares for an estimated $27,572.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Invivyd, Inc. Hedge Fund Activity
We have seen 29 institutional investors add shares of Invivyd, Inc. stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,662,750 shares (-68.5%) from their portfolio in Q2 2025, for an estimated $2,618,866
- FMR LLC removed 1,913,583 shares (-92.8%) from their portfolio in Q2 2025, for an estimated $1,368,211
- MILLENNIUM MANAGEMENT LLC added 1,249,093 shares (+inf%) to their portfolio in Q2 2025, for an estimated $893,101
- DEEP TRACK CAPITAL, LP removed 1,136,274 shares (-11.7%) from their portfolio in Q2 2025, for an estimated $812,435
- GEODE CAPITAL MANAGEMENT, LLC removed 988,696 shares (-60.8%) from their portfolio in Q2 2025, for an estimated $706,917
- ORBIMED ADVISORS LLC removed 933,500 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $667,452
- MAVERICK CAPITAL LTD removed 729,454 shares (-6.7%) from their portfolio in Q2 2025, for an estimated $521,559
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Invivyd, Inc. Analyst Ratings
Wall Street analysts have issued reports on $IVVD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 08/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/26/2025
To track analyst ratings and price targets for Invivyd, Inc., check out Quiver Quantitative's $IVVD forecast page.
Invivyd, Inc. Price Targets
Multiple analysts have issued price targets for $IVVD recently. We have seen 2 analysts offer price targets for $IVVD in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $3.0 on 08/19/2025
- Patrick Trucchio from HC Wainwright & Co. set a target price of $5.0 on 06/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
